Sirtex Medical Limited

Sirtex Medical Limited

Sirtex Medical Limited is an Australian medical device company headquartered in Sydney, manufacturing SIR-Spheres Y-90 resin microspheres for selective internal radiation therapy (SIRT) in liver cancer. The product has regulatory approvals including FDA clearance for unresectable hepatocellular carcinoma (HCC), metastatic colorectal cancer (mCRC), intrahepatic cholangiocarcinoma (iCCA), and neuroendocrine tumor (mNET) liver metastases. The company's website provides region-specific access controls, including a gated section for healthcare professionals and separate content for journalists. SIR-Spheres are indicated as a second-line treatment for mCRC patients refractory to or intolerant of chemotherapy, and as a primary or adjunct therapy in HCC, iCCA, and hepatic mNET. The single product is administered via hepatic artery catheterization, delivering targeted radiation to liver tumors while sparing healthy tissue. The company distributes globally but restricts access to certain markets based on local regulations, notably blocking access from France. As of September 2025, Sirtex updated its product labeling to expand indications to include unresectable iCCA and hepatic metastases from neuroendocrine tumours. The company's digital presence includes a virtual booth for healthcare professionals and region-specific content portals. No information on team size, ownership, or financial data is publicly available from the website. Sirtex operates as a pure-play medical device manufacturer rather than a family office or investment entity. Its structural distinctiveness lies in its single-product focus on Y-90 microspheres, with regulatory approvals across multiple liver cancer types creating a specialized therapeutic franchise. The company's ownership structure and capital deployment strategy remain undisclosed.